BofA raised the firm’s price target on Cytokinetics (CYTK) to $62 from $56 and keeps a Neutral rating on the shares. After incorporating the latest feedback from key opinion leaders, the firm is “modestly” increasing its aficamten forecasts, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics’ Aficamten Faces Competitive and Regulatory Challenges: Hold Rating Maintained
- Verisign, HEICO, Transdigm, Albertsons, Cytokinetics: Insider Moves Unveiled!
- Cytokinetics price target raised to $82 from $71 at Barclays
- Cytokinetics price target raised to $56 from $52 at BofA
- Promising Trial Results and Safety Profile of Aficamten Boost Cytokinetics’ Stock Outlook